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Abstract 21	  
The aim of this work was to evaluate the suitability of stereolithography (SLA) to fabricate 22	  
drug-loaded tablets with modified-release characteristics. The SLA printer creates solid 23	  
objects by using a laser beam to photopolymerise monomers. In this work polyethylene glycol 24	  
diacrylate (PEGDA) was used as a monomer and diphenyl (2,4,6-trimethylbenzoyl) 25	  
phosphine oxide was used as a photo-initiator. 4-aminosalicylic acid (4-ASA) and 26	  
paracetamol (acetaminophen) were selected as model drugs. Tablets were successfully 27	  
printed and formulations with different properties were fabricated by adding polyethylene 28	  
glycol 300 (PEG 300) to the printing solution. The loading of paracetamol and 4-ASA in the 29	  
printed tablets was 5.69% and 5.40% respectively. In a realistic dynamic dissolution 30	  
simulation of the gastrointestinal tract, drug release from the tablets was dependent on the 31	  
composition of the formulations, but independent of dissolution pH. In conclusion SLA 3DP 32	  
technology allows the manufacture of drug loaded tablets with specific extended-release 33	  
profiles. In the future this technology could become a manufacturing technology for the 34	  
elaboration of oral dosage forms, for industrial production or even for personalised dose. 35	  
 36	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1. Introduction 41	  
3-dimensional printing (3DP) is becoming an increasingly popular technology, which provides 42	  
the ability to fabricate structures of precise geometries. The first technology used for printing 43	  
3D structures in pharmaceutics was achieved by inkjet printing a liquid binder solution onto a 44	  
powder bed (Rowe et al., 2000; Wu et al., 1996). The process begins by spreading a layer of 45	  
powder onto a piston plate, followed by addition of liquid binder solution to bind the powder 46	  
particles together. The process is repeated until the desired geometry is created (Katstra et 47	  
al., 2000). This is the method used to manufacture Spritam®, the first 3D printed medicine to 48	  
be approved by the FDA. However, powder-bed printing limits the geometries of the shapes 49	  
that can be printed (in particular, cavities are difficult to incorporate). 50	  
 51	  
Fused-deposition modeling (FDM) is another type of 3DP technology. Here, extruded 52	  
polymer filaments are melted into a semi-liquid state when passed through a heated nozzle. 53	  
The softened filaments are then deposited onto a build platform in a layer by layer process to 54	  
harden (Goyanes et al., 2014). One of the advantages of this technology is higher resolution 55	  
compared with powder-bed printing, which allow creation of more complex scaffolds and to 56	  
achieve better dosing accuracy (Goyanes et al., 2015b). FDM also offers advantages of good 57	  
mechanical strength (Chia and Wu, 2015), and the printed dosage forms can be designed to 58	  
achieve different releases profile by modifying the infill percentage, 3D model design or 59	  
surface area of the formulation (Goyanes et al., 2014; Goyanes et al., 2015e; Goyanes et al., 60	  
2015f). A challenge for FDM is the limited choice of thermoplastic materials with good melt 61	  
viscosity properties for extrusion. Another disadvantage for FDM is the inability to load 62	  
temperature sensitive substances during extrusion due to the high processing temperature. 63	  
In a previous study, approximately 50% of the model drug 4-aminosalicylic acid (4-ASA) was 64	  
degraded during 3D printing (Goyanes et al., 2015a). 65	  
 66	  
Stereolithography (SLA) is a further type of 3DP technology, widely used in the field of tissue 67	  
engineering (Arcaute et al., 2010; Arcaute et al., 2006). In this case, production of the object 68	  
is based on the solidification of a liquid resin by photopolymerization. A laser is focused on to 69	  
a specific depth in a vat of resin, causing localized polymerization (and so solidification). 70	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Solidification is repeated in a layer by layer manner until a solid, 3D object is produced 71	  
(Melchels et al., 2010). In SLA printing, the energy imparted by the laser is important and is 72	  
influenced by the power of the light source, the scanning speed, the exposure time and the 73	  
amount of polymer and photoinitiator (Chia and Wu, 2015). The major advantage of SLA 74	  
printing is its versatility, as drugs can be mixed with the photopolymer prior to printing, and 75	  
become trapped in the solidified matrices. SLA is also superior to other 3DP techniques in 76	  
terms of resolution (20 µm in comparison with 50-200 µm for other fabrication technology), 77	  
(Melchels et al., 2010), which is limited only by the width of the focused laser. An additional 78	  
benefit is that localized heating is minimized during printing, which may mean the technique is 79	  
more suited to fabrication of dosage forms encapsulating thermally labile drugs. The main 80	  
drawbacks of SLA technology are the limited number of photocrosslinkable polymers that are 81	  
available, and the fact these materials are currently not on the generally recognized as safe 82	  
(GRAS) list. Over the past few years a number of photocrosslinkable polymers have been 83	  
developed, such as Poly(ethylene glycol) diacrylate (PEGDA) (Chan et al., 2010; Vehse et al., 84	  
2014), poly(2-hydroxyethyl methacrylate) (pHEMA) (Hanson Shepherd et al., 2011), 85	  
poly(ethylene glycol) dimethacrylate (PEGDMA) (Arcaute et al., 2006; Dhariwala et al., 2004) 86	  
and poly(propylene fumarate)/diethyl fumarate (PPF/DEF) (Fisher et al., 2002).  87	  
 88	  
To the best of our knowledge, there has been no attempt to explore the potential of SLA 89	  
printing to fabrication of unit-dose, oral modified-release dosage forms. Thus, the specific aim 90	  
of this study was to evaluate the suitability of printing drug loaded tablets by SLA printing. 91	  
4-ASA and paracetamol were chosen as model drugs, the former because it is known to be 92	  
thermally labile (and to degrade significantly when printed by FDM machines) (Goyanes et al., 93	  
2015a) and the latter because it is thermally stable and has previously been printed using 94	  
FDM printing (Goyanes et al., 2015e). The effect of polymer composition on drug release 95	  
kinetics was also evaluated. 96	  
 97	  
2. Materials and methods 98	  
Poly(ethylene glycol) diacrylate (PEGDA, average MW 700), Poly(ethylene glycol) (PEG 300, 99	  
average MW 300) and diphenyl(2,4,6-trimethylbenzoyl) phosphine oxide (DPPO) and 100	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paracetamol (MW 151.16) were purchased from Sigma-Aldrich, UK. 4-Aminosalicylic acid 101	  
(4-ASA, MW 153.14) was purchased from Acros Organics, UK. The salts for preparing the 102	  
buffer dissolution media were purchased from VWR International Ltd., UK.  103	  
 104	  
2.1 Preparation of photopolymer solution 105	  
PEGDA and PEG 300 were the primary materials used to prepare the photoreactive solutions. 106	  
PEGDA and PEG 300 were mixed in ratios of 9:1, 6.5:3.5 or 3.5:6.5 (v/v) to a total volume of 107	  
20 mL. DPPO was then added to the mixture at a concentration of 1% (w/v). The solution was 108	  
thoroughly mixed for at least 8 hours until the photoinitiator was dissolved completely. 109	  
Paracetamol or 4-ASA was then added to the solution to a concentration of 5.9% (w/w) 110	  
(Table 1).  The solution was mixed thoroughly to dissolve the drug completely, and the 111	  
resulting photopolymer solution was loaded into the printer. 112	  
 113	  
2.2 Printing dosage forms 114	  
A commercial Form 1+ SLA 3D printer (Formlabs Inc, USA) equipped with a 405nm laser was 115	  
utilized for printing tablets. The printer allows fabrication of objects with a resolution of 300 116	  
microns and a layer thickness of 25, 50, 100 or 200 microns. The templates used to print the 117	  
tablets were designed with Autodesk Meshmixer 2014® (Autodesk Inc., USA) and exported as 118	  
a stereolithography file (.stl) into the 3D printer software (Preform Software v. 1.9.1, Formlabs, 119	  
UK). The basic selected 3D geometry was a torus, 11mm diameter x 4mm height, with a 120	  
central hole of 3mm diameter. The material was set up as flexible and the layer thickness was 121	  
0.1mm. Five tablets were printed at the same time for each formulation. 122	  
 123	  
2.3 Environmental scanning electron microscopy (ESEM)  124	  
The Surface and cross-section images of the printed tablets were captured with a FEI Quanta 125	  
200F Scanning Electron Microscope (FEI, UK) to evaluate the microstructure of the devices. 126	  
The voltage and working distance were set at 5 V and 50 mm, respectively. The samples 127	  
were not coated and pictures were taken under environmental-pressure conditions. Pictures 128	  
of the devices were taken with a Nikon CoolpixS6150 with the macro option of the menu. 129	  
 130	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2.4 X-ray powder diffraction (XRPD) 131	  
The 3D printed discs (23mm diameter x 1mm height) with and without drugs were analysed, 132	  
together with samples of pure 4-ASA and paracetamol. The X-ray powder diffraction patterns 133	  
were obtained in a Rigaku MiniFlex 600 (Rigaku, USA) using a Cu Kα X-ray source 134	  
(λ=1.5418Å). The intensity and voltage applied were 15 mA and 40 kV. The angular range of 135	  
data acquisition was 3–60° 2θ, with a stepwise size of 0.02° at a speed of 5°/min. 136	  
 137	  
2.5 Determination of drug concentration in the photopolymer solution and 3DP tablets 138	  
Photopolymer solution (0.2 g) was diluted with acetonitrile (20 mL). After thoroughly mixing, 139	  
an aliquot of solution (100 µL) was further diluted with water (900 µL) and the drug 140	  
concentration was determined with HPLC (Hewlett Packard 1050 Series HPLC system, 141	  
Agilent Technologies, UK).  142	  
 143	  
For determination of drug loading in 3DP tablets, the tablet was crushed and placed in a 144	  
volumetric flask with acetonitrile (250 mL) under magnetic stirring overnight (n=2). Samples 145	  
of the solutions were then filtered through 0.45 µm filters (Millipore Ltd, Ireland) and the 146	  
concentration of drug determined with HPLC. 147	  
 148	  
The mobile phase for paracetamol analysis consisted of a gradient system of (A) water 149	  
(adjusted to pH 2 with orthophosphoric acid) and (B) acetonitrile. The mobile phase was 150	  
pumped at a flow rate of 1 mL/min under the following gradient program: 0-15 min, 5-20% B; 151	  
15-16 min, 20-5% B, through a Luna 5 µm C18 column, 150 x 4.6 mm (Phenomenex, UK), 152	  
maintained at 40 °C. The eluent was screened at a wavelength of 247 nm and the retention 153	  
time was 7.0 min.  154	  
 155	  
Concentrations of 4-ASA in the samples were measured with a mobile phase consisting of 156	  
acetonitrile (24%), water (76%) and orthophosphoric acid (900 µL/L) pumped through a 157	  
Discovery HSF5 column (4.6 x150 mm) maintained at 40ºC. The mobile phase was pumped 158	  
at a flow rate of 1 mL/min and the eluent was screened at a wavelength of 303 nm. The 159	  
injection volume was 20 µL and the retention time was 3.3 minutes. All measurements were 160	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performed in duplicate. 161	  
 162	  
2.6 Dissolution test conditions 163	  
Drug dissolution profiles for the 3D printed tablets were obtained with a USP-II apparatus 164	  
(Model PTWS, Pharmatest, Germany). 1) the formulations were placed in 750 mL of 0.1 M 165	  
HCl for 2 h to simulate gastric residence time, and then 2) transferred into 950 mL of modified 166	  
Hanks (mHanks) bicarbonate physiological medium for 35 min (pH 5.6 to 7); 3) and then in 167	  
modified Krebs buffer (1000ml) (pH 7 to 7.4 and then to 6.5). The modified Hanks buffer 168	  
based dissolution medium (Liu et al., 2011) (136.9 mM NaCl, 5.37 mM KCl, 0.812 mM 169	  
MgSO4.7H2O, 1.26 mM CaCl2, 0.337 mM Na2HPO4.2H2O, 0.441 mM KH2PO4, 4.17 mM 170	  
NaHCO3) forms an in-situ modified Kreb’s buffer (Fadda et al., 2009) by addition of 50 mL of 171	  
pre-Krebs solution (400.7 mM NaHCO3 and 6.9 mM KH2PO4) to each dissolution vessel. 172	  
 173	  
The formulations were tested in the small intestinal environment for 3.5 h (pH 5.6 to 7.4); this 174	  
was followed by pH 6.5, which represents the colonic environment. These parameters were 175	  
selected to simulate typical conditions for intestinal transit of pharmaceutical formulations and 176	  
pH values in different segments of the GI tract in fasted individuals. The buffer capacity and 177	  
ionic composition of the physiological bicarbonate buffers also closely match the buffer 178	  
capacities of the intestinal fluids collected from different parts of the gut in humans (Fadda et 179	  
al., 2009; Goyanes et al., 2015c; Goyanes et al., 2015d; Liu et al., 2011; Varum et al., 2013). 180	  
 181	  
The medium is primarily a bicarbonate buffer in which bicarbonate (HCO3-) and carbonic acid 182	  
(H2CO3) co-exist in an equilibrium, along with CO2 (aq) resulting from dissociation of the 183	  
carbonic acid. The pH of the buffer system can be decreased by purging CO2 (g) in the 184	  
solution, which promotes the formation of carbonic acid. Similarly, an inert gas (such as 185	  
helium), which removes the dissolved CO2 from the solution, increases the pH of the medium. 186	  
The purging of gases is controlled by an Auto pH SystemTM (Merchant et al., 2014), which 187	  
consists of a pH probe connected to a source of carbon dioxide gas (pH-reducing gas), as 188	  
well as to a supply of helium (pH-increasing gas), controlled by a control unit. The control unit 189	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is able to provide a dynamically adjustable pH during testing (dynamic conditions) and to 190	  
maintain a uniform pH value over the otherwise unstable bicarbonate buffer pH.  191	  
 192	  
The paddle speed of the USP-II was fixed at 50 rpm, and the tests were conducted at 37 193	  
+/-0.5 °C (n=3). The percentage drug released from the formulations was determined using 194	  
an in-line UV spectrophotometer (Cecil 2020, Cecil Instruments Ltd., Cambridge, UK) at the 195	  
wavelength of 244nm for paracetamol or 302 nm for 4-ASA. Data were processed using Icalis 196	  
software (Icalis Data Systems Ltd, Berkshire, UK). 197	  
 198	  
3. Results and Discussion 199	  
Paracetamol and 4-ASA were readily dissolved in the photopolymer solution. The colour of 200	  
the paracetamol solution was clear while the 4-ASA solution was light brown. A torus shape 201	  
was selected for 3D printing due to its complexity compared with conventional discs, and 202	  
because of its difficulty in manufacture by conventional production techniques, such as 203	  
powder compaction. In addition, this design offers not only increased surface area over a 204	  
conventional disc, but also a relatively constant surface area during dissolution (Hansson et 205	  
al., 1988; Kim, 1995). The layer thickness was chosen as 0.1mm although this SLA printer 206	  
could achieve the resolution of 0.025mm. The increased layer thickness could significantly 207	  
decrease the printing time.  208	  
 209	  
Drug loaded tablets were successfully fabricated for the first time with the SLA printer 210	  
(Figures 1). 3D printed tablets showed the same colour of the initial photopolymer solution 211	  
and uniformity in size (11.02 ± 0.02 mm diameter x 4.01 ± 0.01 mm height, with a central hole, 212	  
2.98 ± 0.04 mm diameter). 213	  
 214	  
The theoretical drug loading of the formulations was selected as 5.9% (w/w) to avoid solubility 215	  
issues of the drugs into the PEG/PEGDA systems. The loading of paracetamol and 4-ASA in 216	  
3DP tablets is similar to that in the photopolymer solution (Table 1). The minor decrease of 217	  
drug recovery in the printed tablets compared to that in photopolymer solution could be 218	  
because of the incomplete drug extraction from drug-polymer matrix. The drug loading in 3DP 219	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tablets is similar to the theoretical drug loading, indicating no drug was degraded during the 220	  
3D printing process. This fact is especially relevant for 4-ASA since the degradation of 4-ASA 221	  
using FDM 3D printing has been previously reported (Goyanes et al., 2015a). In that study 222	  
approximately half the drug was degraded during extrusion through the heated nozzle of the 223	  
printer. The results from the SLA printing suggest that fabrication of thermally labile drugs can 224	  
be achieved. Drug loading could be easily calculated by determining the drug concentration 225	  
of photopolymer solution because no drug loss occurs during the printing process. In contrast, 226	  
when preparing the filaments for FDM printer, drug loading was sometimes lower than 227	  
expected due to the adherence of powered drug to the walls of the containers during 228	  
extrusion or irregular extrusion of components (Goyanes et al., 2015b). Another advantage 229	  
over FDM 3DP is that the printing is a one-step method, without need of previous processes, 230	  
just dissolution of the drug in the printing solution. 231	  
 232	  
 233	  
 234	  
XRPD data shows that both 4-ASA and paracetamol are in an amorphous state within the 235	  
tablets, as no peaks appeared in the patterns of the formulations (Figure 2). The drug is 236	  
completely dissolved in the photopolymer solution and according to these results there is no 237	  
Table 1. Drug concentration in photopolymer solution and 3DP tablets 
4-ASA formulations 
4-ASA concentration in 
photopolymer solution  
(%, w/w) 
4-ASA loading in 3DP 
tablets (%, w/w) 
% Drug remaining 
after printing 
90%PEGDA/10%PEG300 5.75 ± 0.03 5.28 ± 0.04 91.8 
65%PEGDA/35%PEG300 5.76 ± 0.13 5.44 ± 0.04 94.4 
35%PEGDA/65%PEG300 5.72 ± 0.19 5.48 ± 0.00 95.9 
Mean 5.75 ± 0.12 5.40 ± 0.09 94.1 
    
Paracetamol formulations 
Paracetamol concentration in 
photopolymer solution  
(%, w/w) 
Paracetamol loading in 
3DP tablets (%, w/w) 
% Drug remaining 
after printing 
90%PEGDA/10%PEG300 6.17 ± 0.07 5.97 ± 0.02 96.6 
65%PEGDA/35%PEG300 5.75 ± 0.14 5.56 ± 0.01 96.7 
35%PEGDA/65%PEG300 5.83 ± 0.38 5.55 ± 0.11 95.1 
Mean 5.92 ± 0.27 5.69 ± 0.22 96.1 
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crystallization of the drug during the photopolymerization process. The ESEM pictures of the 238	  
cross section of the tablets confirm this extent and no crystals of drugs are observed (Figure 239	  
3). On the surface of the torus it is possible to observe the different layers formed to create 240	  
the final object. 241	  
 242	  
The 3D printed tablets were tested in the dynamic in vitro model, which simulates gastric and 243	  
intestinal conditions of the GI tract (Goyanes et al., 2015d). The dissolution profiles of 4-ASA 244	  
and paracetamol loaded tablets show that drug release commences in the gastric phase and 245	  
continues during the intestinal phase for all formulations (Figures 4). The drug release is not 246	  
affected by the pH of the media, indicating that the formulations are pH independent. These 247	  
results differ from those reported by (Vehse et al., 2014) where drug release from matrix 248	  
scaffolds 3D printed using the same technology was considerably faster. These different 249	  
profiles could be explained on the composition of the 3D printed object and on the 3D design 250	  
of the formulation. 251	  
 252	  
Changes in the ratios of PEGDA/PEG 300 did play an important role in drug release rates. 253	  
For paracetamol loaded tablets, formulations with a low percentage of PEGDA generally 254	  
showed faster release rates. Almost 100% of paracetamol was released after 10 hours from 255	  
the formulations containing 35% PEGDA, while only 84% and 76% release after 10 hours 256	  
was measured for formulations containing 65% and 90% PEGDA, respectively. Similar trends 257	  
were observed for the 4-ASA formulations. 4-ASA tablets with 35% PEGDA showed fastest 258	  
release, with complete release within 9 hours. Interestingly, the 4-ASA formulations with 65% 259	  
PEGDA and 90% PEGDA showed more similar drug release profiles. The reduction in the 260	  
concentration of PEGDA probably increases the drug release rate because of a lower degree 261	  
of cross-linking in the tablet matrix. PEG 300 itself cannot crosslink, so increasing the 262	  
proportion of this polymer means greater molecular mobility in the tablet core and a greater 263	  
likelihood of dissolution during testing. Images of the tablets before and after the dissolution 264	  
test (after dried), show a reduction of the size of the tablets when the concentration of PEG 265	  
300 is high (Figure 5), indicating that the PEG300 gets released together with the drugs. 266	  
 267	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The dissolution data therefore suggest that controlled release could be achieved by selecting 268	  
suitable concentration of each polymer in photopolymer solution, as a faster drug release can 269	  
be obtained by reducing the percentage of PEGDA. Therefore, SLA printer also has a 270	  
potential to design an immediate release dosage form by choosing the suitable 271	  
PEGDA/PEG300 ratio. 272	  
 273	  
4. Conclusions 274	  
Tablets containing 4-ASA and paracetamol were successfully produced with an SLA printer. 275	  
This technology offers a simple, fast method to fabricate drug-loaded tablets with high 276	  
resolution. Compared with FDM 3D printing, SLA printing reduces drug degradation and so 277	  
offers an alternative route to produce tablets incorporating thermo-sensitive drugs.  278	  
 279	  
Varying the percentage of crosslinkable polymers in the tablets modulates the drug 280	  
dissolution profiles. Higher ratios of PEGDA reduce the dissolution rate while higher 281	  
concentration of PEG 300 promotes drug release.  282	  
 283	  
SLA 3D printing may be considered as an appropriate method to manufacture 284	  
modified-release oral dosage forms, for industrial production or even for personalised dose. 285	  
 286	  
  287	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